Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639875 | 0.88 | IDE (0.43) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5637765 | 0.87 | IDE (0.49) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5637408 | 0.86 | IDE (0.48) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5637707 | 0.86 | ALOX5 (0.54) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5639091 | 0.85 | IDE (0.49) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5639171 | 0.85 | IDE (0.52) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5639000 | 0.83 | IDE (0.48) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5639763 | 0.83 | IDE (0.50) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5640638 | 0.83 | IDE (0.48) | IDEMEN1KMT2ACLK1HTT | |
| SCHEMBL5638850 | 0.82 | IDE (0.49) | IDEMEN1KMT2ACLK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| CN-1678586-A | Substituted quinoline CCR5 receptor antagonists | SCHERING AG (DE) | 2005-10-05 | — | — | CN | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | IDE 4855/4885MEN1 4119/4885KMT2A 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.